Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 2:1. Implied volatility suggests the market is anticipating a move near 16.2%, or 44c, after results are released. Median move over the past eight quarters is 2.6%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Largest borrow rate increases among liquid names
- INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints
- INmune Bio options imply 14.9% move in share price post-earnings
- INmune Bio Releases Video on Alzheimer’s Trial Results
- INmune Bio announces video detailing findings from Phase 2 MINDFuL trial